Integrated Process Model Applications Linking Bioprocess Development to Quality by Design Milestones

Maximizing the value of each available data point in bioprocess development is essential in order to reduce the time-to-market, lower the number of expensive wet-lab experiments, and maximize process understanding. Advanced in silico methods are increasingly being investigated to accomplish these go...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Christopher Taylor, Lukas Marschall, Marco Kunzelmann, Michael Richter, Frederik Rudolph, Judith Vajda, Beate Presser, Thomas Zahel, Joey Studts, Christoph Herwig
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
QbD
T
Acceso en línea:https://doaj.org/article/53b6d903e149417d90f0b2951937ec32
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Maximizing the value of each available data point in bioprocess development is essential in order to reduce the time-to-market, lower the number of expensive wet-lab experiments, and maximize process understanding. Advanced in silico methods are increasingly being investigated to accomplish these goals. Within this contribution, we propose a novel integrated process model procedure to maximize the use of development data to optimize the Stage 1 process validation work flow. We generate an integrated process model based on available data and apply two innovative Monte Carlo simulation-based parameter sensitivity analysis linearization techniques to automate two quality by design activities: determining risk assessment severity rankings and establishing preliminary control strategies for critical process parameters. These procedures are assessed in a case study for proof of concept on a candidate monoclonal antibody bioprocess after process development, but prior to process characterization. The evaluation was successful in returning results that were used to support Stage I process validation milestones and demonstrated the potential to reduce the investigated parameters by up to 24% in process characterization, while simultaneously setting up a strategy for iterative updates of risk assessments and process controls throughout the process life-cycle to ensure a robust and efficient drug supply.